PubMed Health⌕ Search

PubMed · 12888310

Intractable epilepsy management: an EEG-oriented approach.

Abstract

Intractable epilepsy has always posed a challenge to management; conventional, surgical and alternative techniques available so far (e.g., vagal nerve stimulation, i.e. VNS). The author has attempted to search for a novel alternative (drug-regime) approach to its management to minimise any invasive technique or surgery. The drug-regime is based primarily on EEG-background picture (namely synchronisation and de-synchronisation), which the author claims plays a crucial role in epileptogenesis and/or enhancement of epileptic recruitment. Thus an EEG (both in wake and sleep states) shall be a pre-requisite. The novel drug-regime promises to alter the cortical background-activity in a manner to render it un-favorable for epileptogenesis/enhancement of epileptic recruitment, thereby attempting to produce control over Intractable Epilepsy. The new drug-regime, by virtue of its properties to alter the EEG-background activity, thus could enhance the efficacy of conventional treatment and together, they could form a highly effective management for Intractable Epilepsy, thus minimising the intervention of invasive techniques like VNS and epilepsy brain surgery.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Harinder Jaseja. 2003. Intractable epilepsy management: an EEG-oriented approach.. https://doi.org/10.1016/s0306-9877(03)00150-6

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

A double-blind placebo-controlled trial of zonisamide (zonegran) in the treatment of essential tremor.

Medical therapy for essential tremor (ET), a common movement disorder, is often inadequate. We performed a double-blind placebo-controlled randomized trial to evaluate the efficacy and tolerability of zonisamide (ZNS), an antiepileptic agent, in treating ET. Twenty patients (mean age, 60 +/- 15 years) with ET were randomized to receive ZNS or placebo. ZNS was initiated at a dosage of 100 mg/day and escalated to 200 mg/day at day 14. Patients were evaluated by accelerometry and the Fahn-Tolosa-Marin (FTM) rating scale at baseline and days 14 and 28, as well as the Clinical Global Impression (CGI-C) scale at day 28. At endpoint, subjects assigned to ZNS were taking a mean dosage of 160 +/- 50 mg/day. There were no significant improvements in the FTM total score or its subsections. Tremor amplitude as assessed by accelerometry significantly improved in the ZNS group compared to the placebo group at endpoint relative to baseline (-0.50 +/- 0.72 vs. 0.30 +/- 0.79 m/s(2); P = 0.03). On the CGI-C, 60% (n = 6) of patients in the ZNS group felt that their tremor was unchanged, while the remaining patients felt that their tremor was "minimally improved." Thirty percent (n = 3) of patients taking ZNS discontinued the study due to side effects (fatigue, headache, paresthesias) while taking 100 mg per day. ZNS did not provide significant improvements in clinical rating scales at study endpoint compared to placebo and was only modestly well tolerated. ZNS was effective in reducing tremor amplitude as measured by accelerometry.

Anticonvulsants↗